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Objectives: To estimate the prevalence of HCV and HIV serologic markers and related factors among entrants to the 
main southeastern French prison. 
Methods: During the mandatory consultation at the STD clinic of the Marseilles Prison (HIV counseling, and syphilis/HIV 
screening), physicians also offered HCV serologic testing to each entrant. Inmates were interviewed face to face by a 
physician with a standardized questionnaire. 
Resutts: In total, 391 of 41 1 new inmates (89%) participated in the survey; 79% were male, 75% were aged 18-35 years, 
and 23% were injecting drug users (IDUS). Twenty per cent of the IDUs admitted that they had shared their injection 
equipment during the last 12 months. Of the 391 new inmates, 104 (27%) were HCV positive (91% among IDUs) but only 
45 of 104 (43%) knew their seropositivity status; 23 of 389 (6%) were HIV positive (21% among IDUs). 
Conclusions: This survey underlines the high HCV and HIV seroprevalence among entrants to French prisons, 
especially injecting drug users, and the high proportion of inmates at risk for these infections as well. There is an urgent 
need for education and screening programs in prison and also in the at-risk free-living populations. 
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INTRODUCTION 
In many first world countries, hepatitis C emerged as a 
major public-health issue in the 1990s. Seroprevalence 
surveys have been carried out in various populations, 
especially among at-risk populations such as blood 
recipients [I] and injecting drug users (IDUS) [2-51. 
In France, HCV seroprevalence was estimated in 
1994 at 1.2% of the general population [6,7]. The 
prevalence of serum antibodies to hepatitis C virus 
(HCV) among IDUs was found to be 72% and 67% in 
northern and southwestern France respectively [8,9]. 
A previous study carried out in the largest prison 
in southeastern France showed that prisoners very often 
reported risk behavior before incarceration (injecting 
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drug use, multiple sexual partners, sex with IDUs or 
with HN-seropositive partners) [lo] and during incar- 
ceration as well [ll]. Whereas H N  seroprevalence has 
already been investigated in some European prisons, 
including southeastern France [12-141, the prevalence 
of serologic markers against HCV among European 
prisoners is st i l l  poorly documented. Some surveys 
carried out among Italian and Norwegian prisoners 
found highlevels ofHCV seroprevalence [15,16]. Only 
one survey has been carried out among French 
incarcerated IDUs, in whom HCV seropositivity was 
found to be 80% [17]. 
Because the size of the prison population, especi- 
ally injectors, has dramatically increased in the majority 
of developed countries, it is necessary to evaluate the 
need for implementing screening programs and to find 
appropriate resources to implement them in a context 
of limited funding and s&. We carried out such a 
survey to evaluate a hepatitis B immunization program, 
the results of which have already been published [18]. 
Another objective of that study was to estimate the 
seroprevalence of antibodies against HCV and HIV, and 
to record related factors. 
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M€IHODS 
French prisoners are routinely offered HIV counseling 
on entry into prison. HIV and syphilis screening are 
also offered in t h i s  context at the STD clinic by a 
physician who is independent of the prison adminis- 
tration, but, whereas syphilis testing is mandatory for 
ill sentenced persons, HIV testing is not. These tests 
are h e  and anonymous: the penitentiary administra- 
tion is not told the inmates' serostatus; and the lab- 
oratory which tests the sera sees only numerical codes- 
these are Werent &om the identification numbers 
given by the penitentiary administration when the 
inmates are incarcerated. The medical chief of the 
prison, who is also independent of the prison adminis- 
tration, is informed by the physician of the STD clinic 
only ?fter the inmates have given their consent. 
The prison in Marseilles is one of the largest 
French prisons and holds about 2000 prisoners, 75% on 
remand (awaiting trial) and 25% on short-term 
sentences. Between March and December 1995, we 
invited male and female new entrants to participate in 
a seroprevalence survey for markers of viral hepatitis B 
and C, and to be immunized against hepatitis B. Due 
to limited staf€ and funding resources, but to ensure 
sufticient statistical power, all women were invited, but 
only every second male new inmate was invited to 
participate in the survey. To avoid selection bias, the 
physicians invited only those male entrants who had an 
even identification number. This number is a routine 
one given by the penitentiary administration and not 
by the medical staf€. Prisoners transferred h m  another 
prison or incarcerated in high-security cells (<0.5% of 
the imprisoned population) were excluded h m  the 
study. prelirmnary information on the objectives of the 
study was posted in different places in the prison. The 
physician who offered serologic testing and immuniz- 
ation was independent of the penitentiary administra- 
tion and was not obliged to communicate testing results 
to the administration. Each participant gave written 
consent. A standardized face-to-face questionnaire was 
completed by the physicians to establish socio- 
demographic fearures; any history of STD, viral hepatitis 
and immunization against HBV; HCV and HIV status; 
intravenous drug use; and s d  behavior. A serial 
numerical code allowed us to link the anonymous 
questionnaire to testing results. No information in the 
questionnaire could lead to indirect disclosure of 
identity (no interview date, incarceration date or birth 
date). 
Serum specimens were tested for antibodies to 
HCV with two third-generation ELISA tests (Ortho 
3.0 Diagnostics Systems, Raritan, NJ, USA; Murex 
Test, Murex Diagnostics, Dartford, UK). The sensitiv- 
ities of these ELISA tests were estimated at 1Wh and 
97% respectively [19,20]. A sample was considered 
positive ifboth ELISA tests were positive with ratios of 
more than 4, or when positivity was confirmed by an 
immunoblot assay (Murex HCV Immunoblot Assay; 
RIBA 3 Test, Chiron Corporation, Emeryville, Ca, 
USA). Alanine aminotransferase (ALT) was tested for 
HCV-infected prisoners; HCV RNA sequences were 
extracted, reverse transcribed and amplified [21,22]. 
HIV serostatus was tested with two ELISA tests (Vidas 
BioMCriew, Strodia Bayer) and one Western blot 
(Genelabs Diagnostics DBL 2.2.). HIV-positive results 
were confirmed on another specimen. 
Statistical analysis was performed using the chi- 
square test for univariate analysis and the logistic 
regression model for multivariate analysis (Statistical 
Package for Social Sciences 7.5). 
RESULTS 
Among the 441 eligible prisoners, 391 (89%) agreed to 
participate in the survey; 75% were aged 18-35 years, 
21% were women, 83% lived in Marseilles, 56% were 
unemployed, 71% had less than 12 years of education, 
41% reported that they had no health insurance, and 
34% had been incarcerated at least once before and 
were known to the physicians providmg counsehng and 
testing in the prison. Participants and non-participants 
did not differ sigtllficantly in socio-demographic charac- 
teristics and risk behavior (including injecting drug 
use); in particular, the proportion of participants who 
had ever been tested for HCV did not differ (12% 
versus 15%, p 0 . 7 ) .  Immunization against hepatitis B 
was declared more fiequently by participants than by 
non-participants (men 14% versus 8% (p=O.O4); women 
33% versus 18% (p=0.09)). 
Sexual and injecting behavior 
Men reported having had more than one sexual partner 
during the last 12 months more hquently than did 
women (47% versus 23% pC10-2); however, women 
reported having had sexual intercourse with an IDU 
partner more fi-equently than did men (20% versus 8%; 
Twenty-three per cent of inmates (891391) declared 
that they had injected drugs at some time. This behavior 
was more fi-equently declared by women than by men, 
especially during the last 12 months (25% versus 16%; 
p0.06) .  Syringe and needle sharing during the last 12 
months was fi-equently reported by both men and 
women (24% versus 35%; ~ ~ 0 . 3 2 ) ;  spoon and filter 
sharing was reported sigdcantly more often by 
women than by men (60% versus 29%; p=0.02). The 
pc10-2). 
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proportion of lDUs who declared that they had had 
two or more heterosexual partners during the last 12 
months or had had homosexual intercourse did not 
difGer fiom that of non-IDUs (Table 1). Among 
prisoners who declared that they had had two or more 
sexual partners during the last 12 months and at least 
one IDU sexual partner during the last 12 months, 
three of 21 (14%) reported that they had not used 
condoms for penetrative sex, and 11 of 21 (52%) for 
oral sex. There was no si@icant eerence  between 
IDUs and non-IDUs. On the other hand, IDUs were 
more likely than non-IDUs to report sexual intercourse 
with an IDU or an HIV-infected partner. 
HCV and HIV seroprevalence 
Seventy-one inmates tested positive in both ELISA 
HCV tests; 35 tested positive by one ELISA test and 33 
of 35 were confirmed by the immunoblot technique. 
Overall, 104 of 391 inmates (27%) tested positive for 
HCV antibodies (Table 2). Among the anti-HCV 
positives, 34 of 100 had raised ALT levels and 65 of99 
were HCV FWA positive. The proportion of inmates 
with raised ALT did not M e r  sigmficantly, whether or 
not they were positive for HCV RNA. HCV seropre- 
valence was sigmficantly higher among IDUs than non- 
IDUs (91% versus 7.6%; P < ~ O - ~ ) ,  and among HIV- 
infected than non-HIV infected inmates (87% versus 
23%; P < ~ O - ~ ) ;  78% of HCV-positive inmates were 
IDUs and 20% were also HIV positive. 
Table 3 lists the predictors for the presence of HCV 
seromarkers, Multivariate analysis showed that only age 
and injecting drug use were significantly related to 
HCV seromarkers. Among inmates who tested positive 
for HCV, 45 of 104 (43%) knew that they were positive 
Table 1 Main characteristics and risk behavior during the last 12 months before incarceration among injecting and non- 
injecting drug users (n=391) 
lDUs n (%) non-IDUs n (%) Total n (%) P 
Age 
18-24 y ~ a n  
25-34 years 
>34 years 
Male 
Female 
SeX 
Sexual intercourse 
No partner 
One partner 
Two or more partners 
NA 
Homosexual intercourse 
YeS 
No 
NA 
IDU sexual partner' 
YeS 
No 
NA 
HIV-infected sexual partner' 
Yes 
No 
NA 
Condom use for penetrative sexb 
Never 
Sometimes 
Always 
Syringe sharing' 
Spoon-filter sharing" 
21 
63 
5 
68 
21 
7 
35 
45 
2 
1 
81 
7 
31 
38 
1 
12 
44 
24 
6 
16 
23 
19/71 
27/71 
(24) 74 
(71) 137 
(5%) 91 
(45) 9 
(55) 228 
(4) 40 
(96) 268 
83 
'Among prisoners who declared at least one sexual partner during the last 12 months. 
bAmong prisoners who declared more than one s e n d  partner during the last 12 months. 
cAmong IDUs who declared that they had injected during the last 12 months. 
dThe analysis was adjusted for age. 
NA, not available. 
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Table 2 HTV seroprevalence and HCV semmarkers accordmg to injecting dru~ use over M e h e  (n=391) 
w u s  non-WUs Total 
n (n=89) (%) 95%CI n (n=302) (%) 95% CI n (n=391) (%) 95%CI p 
HIV 
positive 
NA 
HCV 
NeptiW 
POSitiW 
NCgltiVC 
Hepatitis C 
=Pow 
YCS 
No 
ALT 
Increased 
Not increased 
NA 
HCV-RNA' 
Positive . 
NA 
Negvive 
18 20.5 
70 79.5 
1 
81 91 
8 9 
40 49.4 
41 50.6 
26 32.9 
53 67.1 
2 
54 70.1 
23 29.9 
4 
12.9-30.7 5 
- 289 
8 - 
82.6-95.8 23 
- 279 
5 
- 18 
- 
23.0-44.5 8 
13 
2 
- 
- 
61.2-82.3 11 
11 
1 
- 
- 
1.7 
98.3 
7.6 
92.4 
21.7 
78.3 
38.1 
61.9 
50 
50 
0.6-4.2 23 6 
- 359 94 
9 - 
4.9-11.4 104 26.6 
- 287 73.4 
40-5 
3.P-9.0 
- 
4 0 - 5  
22.3-31.3 
- 
- 45 43.3 
- ' 59 56.7 
18.9-61.3 34 34 
- 6 6 6 6  
4 - 
28.8-71.2 65 65.7 
- 34 34.3 
5 - 
0.02 
- 
0.65 
25.0-44.2 
- 
0.08 
55.4-74.8 
aAmong prisoners who tested positive for HCV 
NA, not available. 
Table 3 Predictors of the presence of hepatitis C serornarkers (n=391) 
Variable Number of positives/ Proportion Odds odds ratio in 
number tested marker positive =ti0 p logisticrcgmsion P 
Sex 
Women 26/79 33 1 1 
Men 78/312 25 0.68 0.15 0.76 0.27 
Age 
18-24 
25-34 
>34 
Injecting drug use 
YeS 
No 
22/95 23 1 1 
69/200 35 1.8 ~ 1 0 - 3  1.58 0.17 
13/96 14 0.5 0.82 0.45 
81/89 91 122 40-5 11.2 -40-5 
231302 7.6 1 1 
Previous imprisonment 
Yes 541132 41 2.9 -40-5 1.10 0.96 
No 501259 19 1 1 
Two or more sex partners 511164 31 1.7 0.03 1.23 0.30 
One sex p a e r  421198 21 1 1 
~yringc-shumlf 
YCS 
No 
18/19 94.7 2.3 0.43 - 
46/52 88.5 1 - 
Spoon-filter shuing' 
YS 26/27 96.3 4.1 0.17 - 
No 38/44 86.4 1 
Yes 11/38 29 1.13 0.73 - 
No 931353 26 1 
- 
Almady vaccinated against HBV 
- 
fonly among IDUs. 
HBV, hepatitis B virus. 
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for HCV, and IDUs were more likely than non-IDUs 
to know their HCV serostatus (49% versus 22%; 
p=0.02). Among the IDUs, the proportion of inmates 
who knew their HCV serostatus was hgher among 
those who had been incarcerated before (64% versus 
29%; p=0.002). 
Ninety-eight per cent of participants agreed to be 
HIV tested; 6% tested HIV positive (Table 2). IDUs 
were infected with HIV more often than non-IDUs. 
Among the 23 HIV-infected prisoners, 21 (91%) also 
had anti-HCV antibodles. Multivariate analysis showed 
that only age and injecting drug use were related to the 
presence of HIV antibodies (Table 4). Whereas the 
relationship between knowledge of HIV seropositivity 
and injecting behavior was very significant, that 
between HCV seropositivity and injecting behavior 
was not. Among IDUs who knew their HCV 
seropositivity, 11 of 32 (34%) and 15 of 32 (47%) had 
shared their syringe and their spoon/filter, respectively, 
during the last 12 months. Among IDUs who knew 
their HIV seropositivity, none had shared his syringe 
and two of 13 (15%) had shared a spoon/filter during 
the last 12 months. 
Table 4 Predictors of the presence of HIV seromarkers (n=382) 
DISCUSSION 
This survey underlines the fact that the hgh prevalence 
of risk behavior is common, and there is high HCV and 
HIV seroprevalence among people entering south- 
eastern French prisons. About 27% of incarcerated 
persons were seropositive for HCV, i.e. 20 times the 
proportion in the French general population (1.2%) 
[6,7]. In our study, the HCV seroprevalence among 
IDU inmates was exceedingly high and in agreement 
with estimates reported by other studies carried out 
among fiee-living IDUs in northern France (72%) [8], 
in southwestern France (67%) [9], and in North 
America (77%) [S]. It was also in agreement with 
studies carried out among imprisoned IDUs in 
northern France (80%), A u s d a  (66%), Austria (75%), 
Italy (59%) and Germany (83%) [3,4,16,17,19] . 
In our survey, the participation rate was high (89%). 
Reporting a history of hepatitis B, and previous testing 
for HCV and HIX &d not W e r  sigrufcantly between 
participants and non-participants, which implies that 
conclusions are lkely to be reliable. Although we can- 
not eliminate some selection bias, because vaccination 
Univariate Odds ratio in Variable Number of positives/ Proportion 
number tested marker positive odds ratio p logistic regression P 
Sex 
Women 5/78 6.4 1 1 
Men 18/304 5.9 0.91 0.87 0.90 0.72 
Age 
18-24 
25-34 
>34 
3/93 3.2 1 1 
19/194 9.8 3.26 0.005 1.24 0.69 
1 /95 1.1 0.32 0.50 0.10 
Previous imprisonment 
Yes 15/130 11.5 4 0.001 1.30 0.28 
No 81252 3.2 1 1 
Injecting drug use 
YeS 
No 
S y r i n g h i n g '  
Yes 
No 
18/88 20.5 15 40-5 3.19 4 0 - 5  
5/294 1.7 1 1 
2/19 10.5 0.35 0.18 - - 
- 13/52 25 1 
Spoon-filter sharing? 
Yes 4/27 14.8 0.52 0.30 - - 
No 11/44 25 1 - 
- - One sex partner 9/192 4.7 1 0.28 
Two or more sex partners 121163 7.4 1.62 - 
Homosexual intercourse - YeS 1 14 20 4.2 0.17 - 
No 20/353 5.7 1 - 
'Only among IDUs. 
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against hepatitis B could have been an incentive to take 
part, it is unlikely that people who decided to partici- 
pate differed significantly in HCV seroprevalence; 
indeed, our results showed that inmates who declared 
that they had been vaccinated against HBV before the 
current incarceration did not differ significantly for 
HCV status from those not vaccinated. 
As expected, IDUs were more often infected with 
HCV than non-IDUs. However, the proportion of 
non-IDUs infected with HCV was higher than in the 
general population (7% versus 1.2%). Whereas a report 
of injecting drug use by inmates is in keeping with 
previous ones [11,14], we cannot strictly eliminate 
possible information bias. In spite of the training and 
independence of the physicians of the STD clinic, and 
the conditions of anonymity, some IDUs might have 
not declared their behavior. A history of blood trans- 
fusion before 1991 was not associated with HCV 
positivity; however, it has been shown that declarations 
were not always reliable [23]. Other risk behaviors 
which have not been investigated in our study could be 
involved, such as tattooing, drug s a n g  (e.g. cocaine) 
[24], and nosocomid transmission. 
The high HCV seroprevalence among IDUs calls 
for an increase in harm reduction strategies both 
outside and inside prisons. Many IDUs st i l l  have risky 
behavior on the outside and continue to share injection 
equipment, especially spoons and filters. When we 
compared injecting behavior among HN- and HCV- 
infected inmates, we noticed that those infected with 
HIV were more likely than those infected with HCV 
to use safe injecting behavior. This could be explamed 
by many IDUs infected with HCV not knowing their 
serostatus or not believing that virus C can be trans- 
mitted through equipment sharing; some may also 
believe that hepatitis C is not a serious disease. Several 
studies have also reported risk behavior in prison, such 
as injecting drug use [3,11,13,25] and tattooing, 
another recognized route of HCV transmission 
[11,16,26,27]. Moreover, an outbreak of hepatitis B 
and HIV occurred in a Scottish prison in 1993 1291. 
These arguments justlfy the need for better information 
to be given to inmates and staff, and the implement- 
ation of efficient risk reduction programs in prison. 
Our study showed that, in spite of the high HCV 
seroprevalence, a minority of prisoners h a d y  knew 
their HCV serostatus. It is worthwhile emphasizing that 
many IDUs and HIV-positive prisoners had never been 
screened for HCV before the current incarceration or 
were not aware of their HCV serostatus. Imprisonment 
might be an opportunity to counsel and screen persons 
who are at risk of contracting HCV and have limited 
access to health care. Our study showed that HCV 
testing was well accepted by inmates and that IDUs 
who had been previously incarcerated were more often 
screened for HCR However, the implementation of an 
HCV screening program needs extra resources to train 
physicians and nurses, to offer costly investigations and 
therapies (interferon-a and ribavirin), to educate stA€ 
and prisoners on the risks of contamination, and to 
avoid stigmatizing HCV-infected inmates. As the 
proportion of IDUs in French prisons, as in most prison 
systems, is not well documented and very likely to 
fluctuate over time and in local situations, we do not 
have reliable estimates of the number of HCV positives 
who should be referred and treated. On the basis of a 
conservative estimate of 15% IDUs in French prisons, 
we can estimate that about 8000 IDU inmates are 
infected with HCR If we add the number of non-IDU 
inmates potentially infected with HCV (7% in our 
sample), then we can estimate that a total of 11 500 
inmates should be referred, i.e. about 20% of the 60 OOO 
people incarcerated in French prisons on a given day. 
These elements should be confirmed by M e r  epi- 
demiologic and cost-effectiveness studies, but they 
should encourage decision-makers to consider seriously 
the issue of hepatitis C in prison as a major public- 
health problem. 
The reported HIV seroprevalence was lower than 
that observed in 1992 in the same prison by very similar 
methods (men 5.9% versus 9%; women 6.4% versus 
13.1%) [14]. Since 1990, a decrease in the proportion 
of HIV-infected prisoners has also been observed by the 
national survey undertaken by the Ministry of Justice 
annually on a specified day [30]. This trend is also in 
keeping with national data that have shown the first 
decrease in the number of new AIDS cases and new 
H N  seropositives in France [31]. We also observed a 
decrease in the proportion of IDUs infected by HIV 
(21% in 1995 versus 40% in 1992) [14]. This decrease 
may be explained by the high mortality rate among 
IDUs [32], but also by changes in IDU behavior as 
reported by other French researchers [33]. However, 
the rate of HIV infection among injector inmates 
remains very high. 
In conclusion, t h i s  study, which highl~ghn the 
high prevalence of HIV and HCV infections among 
prisoners, especially drug injectors, should encourage 
public-health decision-makers to spread widely pro- 
grams of HIV and hepatitis C screening and counseling 
in prison and in at-risk populations. 
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